All In MedTech

Device Trial Radar · NCT05641753

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Dec 6, 2022

Primary completion

Jul 1, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Dec 8, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.

Conditions

  • Type 1 Diabetes

Interventions

  • Evolocumab CartridgeDrug

    Injectable PCSK9 inhibitor.

  • Atorvastatin Calcium TabletsDrug

    HMG-CoA reductase inhibitor for oral use.

  • Ezetimibe TabletsDrug

    Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.

  • 18F-FDGDrug

    Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.

  • Angiocatheter 20IVDevice

    Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.

  • J-WireDevice

    Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.

  • GlycoCheck Glycocalyx Measurement SoftwareDevice

    Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Monocyte Platelet Aggregation (MPA) from BaselineTime frame: Baseline, Week 4
  2. Change in Light Transmission Aggregation (LTA) from BaselineTime frame: Baseline, Week 4

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • New York VA Hospital

    New York, New York · Recruiting

  • NYC Health + Hospitals/Bellevue

    New York, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.